The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Author

  • Helena Ågerstam
  • Christine Karlsson
  • Nils Hansen
  • Carl Sandén
  • Maria Askmyr
  • Sofia von Palffy
  • Carl Högberg
  • Marianne Rissler
  • Mark Wunderlich
  • Gunnar Juliusson
  • Johan Richter
  • Kjell Sjöström
  • Ravi Bhatia
  • James C Mulloy
  • Marcus Järås
  • Thoas Fioretos
Show all

Summary, in English

Acute myeloid leukemia (AML) is associated with a poor survival rate, and there is an urgent need for novel and more efficient therapies, ideally targeting AML stem cells that are essential for maintaining the disease. The interleukin 1 receptor accessory protein (IL1RAP; IL1R3) is expressed on candidate leukemic stem cells in the majority of AML patients, but not on normal hematopoietic stem cells. We show here that monoclonal antibodies targeting IL1RAP have strong antileukemic effects in xenograft models of human AML. We demonstrate that effector-cell-mediated killing is essential for the observed therapeutic effects and that natural killer cells constitute a critical human effector cell type. Because IL-1 signaling is important for the growth of AML cells, we generated an IL1RAP-targeting antibody capable of blocking IL-1 signaling and show that this antibody suppresses the proliferation of primary human AML cells. Hence, IL1RAP can be efficiently targeted with an anti-IL1RAP antibody capable of both achieving antibody-dependent cellular cytotoxicity and blocking of IL-1 signaling as modes of action. Collectively, these results provide important evidence in support of IL1RAP as a target for antibody-based treatment of AML.

Department/s

  • Translational Genomic and Functional Studies of Leukemia
  • Division of Clinical Genetics
  • Division of Molecular Medicine and Gene Therapy
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Stem Cell Center
  • Targeted therapies in leukemia
  • StemTherapy: National Initiative on Stem Cells for Regenerative Therapy

Publishing year

2015

Language

English

Pages

10786-10791

Publication/Series

Proceedings of the National Academy of Sciences

Volume

112

Issue

34

Document type

Journal article

Publisher

National Academy of Sciences

Topic

  • Hematology

Status

Published

Research group

  • Translational Genomic and Functional Studies of Leukemia
  • Targeted therapies in leukemia

ISBN/ISSN/Other

  • ISSN: 1091-6490